In major trials, semaglutide and tirzepatide lowered systolic blood pressure by about 5 to 7 mm Hg more than placebo on average, largely alongside weight loss. They are not blood pressure medications, and they can occasionally push pressure too low.
GLP-1 medications tend to lower blood pressure. In the main weight management trials, systolic pressure (the top number) fell about 5 to 7 mm Hg more with semaglutide or tirzepatide than with placebo, on average, and most of that effect tracks with weight loss. These medications are not approved to treat high blood pressure, though, and in a small share of people, especially those already taking blood pressure medication, pressure can drop lower than intended. That makes blood pressure something to monitor, not something to manage on your own.
High blood pressure is one of the most common conditions that travels with excess weight. The CDC reports that 48.1 percent of US adults, about 119.9 million people, have high blood pressure, and only 22.5 percent have it under control. Among adults with obesity, 58 percent have high blood pressure.
Weight loss itself lowers pressure, regardless of the method. A 2003 meta-analysis in the journal Hypertension pooled 25 randomized trials of diet, exercise or both, with 4,874 participants. On average:
This dose-response pattern is the backdrop for the GLP-1 results below. When a medication produces larger average weight loss, a larger average drop in blood pressure is expected.
Blood pressure was a measured outcome in the pivotal weight management trials. These are average results in adults with overweight or obesity, without diabetes; individual responses vary.
| Trial | Duration | Systolic change, medication | Systolic change, placebo |
|---|---|---|---|
| STEP 1 (semaglutide) | 68 weeks | -6.16 mm Hg | -1.06 mm Hg |
| SURMOUNT-1 (tirzepatide, three dose groups) | 72 weeks | -6.6 to -7.7 mm Hg | -1.0 mm Hg |
In STEP 1, published in the New England Journal of Medicine, diastolic pressure also fell more with semaglutide (-2.83 mm Hg) than with placebo (-0.42 mm Hg). The Zepbound prescribing information reports placebo-adjusted systolic reductions of 5.6 to 6.7 mm Hg and diastolic reductions of 3.7 to 4.2 mm Hg across tirzepatide doses in SURMOUNT-1.
Office readings are a snapshot. A 2024 substudy of SURMOUNT-1, published in Hypertension, enrolled 600 participants who wore 24-hour ambulatory monitors at the start and at week 36. Compared with placebo, average 24-hour systolic pressure fell by 7.4, 10.6 and 8.0 mm Hg across the three tirzepatide dose groups. Reductions were seen during both daytime and nighttime.
The authors found that weight reduction was associated with the blood pressure changes, and suggested tirzepatide "may also have effects on BP independent of weight loss." That second point is a hypothesis from the analysis, not an established mechanism.
No. Neither Wegovy nor Zepbound lists high blood pressure as an approved use. Lower readings are a downstream effect seen in trials, not the purpose of the medication. A few practical consequences follow:
The Wegovy prescribing information reports that hypotension (low blood pressure), orthostatic hypotension (a drop when standing) or decreased blood pressure occurred in 1.3 percent of adults on Wegovy injection versus 0.4 percent on placebo. Two details stand out from the label:
Fluid loss deserves its own attention. Both labels warn that gastrointestinal reactions can lead to dehydration severe enough to injure the kidneys, and the Wegovy label links some low blood pressure reactions to that same fluid loss. Our article on hydration during weight loss covers practical habits, and managing GLP-1 side effects covers the gastrointestinal side.
Signs worth reporting to your prescriber include dizziness or lightheadedness, especially when standing up. If you faint, have chest pain, or have severe trouble breathing, call 911.
GLP-1 medications slightly raise resting heart rate on average. The Wegovy label reports mean increases of 1 to 4 beats per minute versus placebo, and the Zepbound label reports mean increases of 1 to 3 beats per minute. In the ambulatory substudy above, 24-hour heart rate rose 2.1 to 5.4 beats per minute compared with placebo. If you track your pulse and see a persistent rise, mention it to your provider.
In STEP 1 and SURMOUNT-1, systolic pressure fell roughly 5 to 7 mm Hg more than placebo on average over 68 to 72 weeks. Some people see more and some see little change. In lifestyle research, larger weight loss was associated with larger drops.
Not on your own. Blood pressure medication should only be changed by the clinician who manages it, based on repeated readings.
Home readings can be helpful to share with your provider, especially if you already take blood pressure medication or notice dizziness. Ask your provider what range to watch for and how often to measure.
Yes. A meta-analysis of 25 lifestyle trials found systolic pressure fell about 1.05 mm Hg per kilogram lost. Medication is one way to reach larger weight loss, not the only one.
If you have high blood pressure or take medication for it, share your recent readings and full medication list with a licensed provider before starting any weight management treatment. They can help you decide whether a GLP-1 is appropriate and how to monitor your pressure along the way. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read article